MEDX ... anybody following? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following?

MEDX 31.58

+0.5%

Nov 5 12:44 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	12/13/2006 3:23:42 AM
	of 2240

Genmab Announces HuMax-ZP3 Cancer Program Wednesday December 13, 3:13 am ET COPENHAGEN, Denmark, Dec. 13 /PRNewswire-FirstCall/ -- Genmab A/S (CSE: GEN - News) announced today its fully human HuMax-ZP3 antibody program. Antibodies in the program target ZP3, a protein that is overexpressed on colon, pancreatic and prostate cancers but is not expressed in critical organs such as the brain, heart, liver and lungs. HuMax-ZP3 has been selected from a panel of over 70 antibodies, and chosen for its tumor fighting properties and binds effectively to tumor cells expressing the ZP3 protein. HuMax-ZP3 potently exhibits the Antibody-Dependent Cellular Cytotoxicity (ADCC) and Complement Dependent Cytotoxicity (CDC) immune system killing mechanisms against ZP3-expressing tumor cells. Furthermore, pre-clinical data from in vivo solid tumor models in SCID mice (mice with deficient immune systems) show impressive anti-tumor effects induced by HuMax-ZP3. "We are encouraged by the pre-clinical profile of the human anti-ZP3 antibodies and hope that HuMax-ZP3 will be effective against solid tumors in patients," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next